Cannabis Clinical Trial
Official title:
Effect of Cannabis Administration and Endocannabinoids on HIV Neuropathic Pain Primary Study - Phase 2
Verified date | May 2024 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Acute cannabis administration is reported to alleviate HIV neuropathic pain (HIV-NP), but there is limited knowledge about the effects of cannabis constituents (delta-9 tetrahydrocannabinol/THC and cannabidiol/CBD), the consequences of long-term cannabis use, and the impact of cannabis on endocannabinoid (EC) function in people living with HIV- NP. Our objective is to address these three fundamental gaps in our knowledge by: 1) examining the acute effects of various CBD/THC products on HIV-NP, 2) utilizing a mHealth text messaging protocol, Individual Monitoring of Pain and Cannabis Taken (IMPACT) to monitor daily real-world cannabis use and changes in pain; and 3) studying the relationship between cannabinoids, EC biomarkers, and chronic neuropathic pain
Status | Completed |
Enrollment | 5 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. the ability to provide informed consent 2. age 18 or older 3. HIV infection documented at the HNRP or assessed by an HIV test at screening; 4. a diagnosis of HIV sensory neuropathy 5. current use of cannabis 6. the ability to describe the THC and CBD content in the products they use, i.e., obtaining cannabis from dispensaries that list THC and CBD content 7. ability to respond to daily text message Exclusion Criteria: 1. meeting criteria for current substance or alcohol dependence 2. traumatic brain injury 3. dementia or Alzheimer's disease 4. psychosis 5. a respiratory condition, i.e., pulmonary disease, that would be exacerbated by inhaling vaporized cannabis 6. history of cardiovascular disease, including myocardial infarction or stroke; 7. uncontrolled hypertension, defined as a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 100 mm Hg 8. pregnancy, breastfeeding, or unwillingness to prevent pregnancy during the cannabis administration portion of the study (using birth control in female participants of child- bearing age) 9. unwillingness or inability to receive or respond to text messages |
Country | Name | City | State |
---|---|---|---|
United States | UC Center for Medicinal Cannabis Research, UC San Diego | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Diego |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase 1 - Numerical Pain Rating Scale (NPRS) | This is a scale from 0 to 10 indicating the self-reported level of pain. 0 is the minimum score, indicating no pain. 10 is the maximum score indicating highest level of pain. | Pain is measured once before they receive study medication and then 2 minutes after drug treatment. | |
Secondary | Phase 1 - Patient Global Impression of Change (PGIC) | This is a 7-point ordinal scale that asks the participant to rate improvement in their pain after drug administration compared to before drug administration. The scale range is 1 to 7. A score of 1 indicates the greatest improvement (reduction) in pain. A score of 7 indicates that pain is worse. | The PGIC was measured two minutes after drug administration. | |
Secondary | Phase 1 - Von Frey Test | This test measures sensitivity to pain causes by physical contact with the skin. The von Frey filament is applied to the dorsum of the more painful foot until bending is observed for 3 seconds. Pain is rated using a visual analog score (VAS). The scale is 0 to 100, where 0 indicates no pain and 100 indicates the worst pain. | The von Frey test was administered before drug administration and two minutes after drug administration. | |
Secondary | Phase 1 - Marijuana Subscale (M-scale) of the Addiction Research Center Inventory (ARCI) | The M-scale has 12 true/false statements describing the subjective effects of marijuana on participants after they take the drug. Each question is scored as 0 or 1. The scale ranges from 0 (minimum score) to 12 (maximum score). A lower score indicates that the participant is experiencing fewer side effects of the drug. A higher score indicates that the participant is experiencing more side effects of the drug. Reported side effects on this scale include dry mouth, slower movements, shaking hands, and having a pleasant feeling. | The M-scale was administered 2 minutes after drug treatment. | |
Secondary | Phase 1 - Levels of the Endocannabinoid Biomarker Anandamide (AEA) | Anandamide levels in plasma were quantified using liquid chromatography-tandem mass spectrometry (LC/MS). | AEA was quantified 60 minutes after drug administration. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04199468 -
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
|
Phase 1 | |
Completed |
NCT04587700 -
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery
|
||
Not yet recruiting |
NCT05899946 -
An Integrated Program to Promote Anti-cannabis Messages
|
N/A | |
Active, not recruiting |
NCT02735954 -
Colorado Marijuana Users Health Cohort
|
||
Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
Completed |
NCT04124432 -
Behavioral Pharmacology of Cannabis and Nicotine
|
Phase 1 | |
Active, not recruiting |
NCT04693884 -
Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise
|
Early Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Active, not recruiting |
NCT03560934 -
Tetrahydrocannabinol (THC) and Sleep
|
Early Phase 1 | |
Recruiting |
NCT04704271 -
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
|
Phase 1 | |
Withdrawn |
NCT03245658 -
The Effect of Cannabis in Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT04911127 -
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
|
Phase 1 | |
Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
Recruiting |
NCT04429568 -
THC Crossover Study
|
N/A | |
Completed |
NCT05554146 -
Pain Inflammation and Cannabis in HIV
|
N/A | |
Not yet recruiting |
NCT05320367 -
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
|
Phase 1/Phase 2 | |
Completed |
NCT02567344 -
Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving
|
N/A | |
Terminated |
NCT03251326 -
Nabilone in Cannabis Users With PTSD
|
Phase 1/Phase 2 | |
Completed |
NCT00176085 -
Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH
|
Phase 1 |